GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Kidney International, Elsevier BV, Vol. 98, No. 6 ( 2020-12), p. 1519-1529
    Type of Medium: Online Resource
    ISSN: 0085-2538
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    detail.hit.zdb_id: 120573-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Wiley ; 2018
    In:  Journal of Clinical Apheresis Vol. 33, No. 4 ( 2018-08), p. 494-504
    In: Journal of Clinical Apheresis, Wiley, Vol. 33, No. 4 ( 2018-08), p. 494-504
    Abstract: Success of peripheral blood stem cell (PBSC) collections depends on patient biological parameters and stable apheresis device performance. We investigated product quality and factors influencing main apheresis procedure outcomes including CD34 + collection efficiency (CE), product volume or platelet CE. We also assessed different CD34 + cell yield prediction algorithms. Autologous PBSC collections by Spectra Optia from myeloma and lymphoma patients were analyzed. Complete blood count (CBC) from patient preprocedure and from collected products were assessed. (1) Product yield was calculated, (2) Product CBC was correlated with patient preprocedure variables, and (3) Predictions of CD34 + yields based on (a) product CD34 + cell concentration in samples after two or four chamber flushes or (b) traditional CE2 benchmark, were compared. 62 procedures in 41 patients were analyzed. 84% of all procedures were run without operator intervention. Median CD34 + CE2 was 56.9% (48.8%‐65.2%) and quite stable irrespective of patient conditions, with minor influence from patient white blood cell (WBC) precounts ( r s  = –.47; P   〈  .001). Platelet loss correlated with WBC precount ( r s  = .46; P   〈  .001), product volume ( r s  = .71; P   〈  .0001) and number of chambers collected ( r s  = .72; P   〈  .0001). CD34 + cell yield was better predicted based on (a) product CD34 + cell concentration from samples after 2 and 4 chamber flushes, respectively ( r s  = .969; P   〈  .0001 and r s  = .9648; P   〈  .0001) than based on (b) CE2 formula ( r s  = .8262, P   〈  .0001). Spectra Optia provides good quality PBSC products with stable and predictable yield regardless of starting conditions. CD34 + sampling of product after few chamber flushes could be used to predict CD34 + yield.
    Type of Medium: Online Resource
    ISSN: 0733-2459 , 1098-1101
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2001633-5
    detail.hit.zdb_id: 604912-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Chemical Society (ACS) ; 2009
    In:  Journal of Agricultural and Food Chemistry Vol. 57, No. 23 ( 2009-12-09), p. 11106-11111
    In: Journal of Agricultural and Food Chemistry, American Chemical Society (ACS), Vol. 57, No. 23 ( 2009-12-09), p. 11106-11111
    Type of Medium: Online Resource
    ISSN: 0021-8561 , 1520-5118
    Language: English
    Publisher: American Chemical Society (ACS)
    Publication Date: 2009
    detail.hit.zdb_id: 1483109-0
    detail.hit.zdb_id: 241619-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 178-178
    Abstract: Hepcidin, a circulating hormone produced primarily by the liver, plays a central role in the regulation of systemic iron homeostasis necessary to ensure sufficient availability of iron for hemoglobin synthesis and other metabolic processes while avoiding the oxidative damage to cells that can result from excess free iron. Hepcidin triggers internalization and degradation of ferroportin, the only known iron export channel from cells into the plasma, which leads to the decrease of dietary iron absorption from duodenal enterocytes and to the sequestration of iron recycled from senescent blood cells within macrophages. Iron overload induces the expression of bone morphogenetic protein 6 (BMP6), a member of the TGF-beta superfamily of ligands, which activates a signaling cascade leading to SMAD1/5/8 phosphorylation, translocation of the phosphorylated SMADs bound to SMAD4 to the nucleus, and upregulation of hepcidin gene transcription. Inactivation of Bmp6 in mice leads to considerably reduced hepcidin production, compared with wild-type mice, and severe hepatic iron overload. However, there are major differences in hepcidin expression and extrahepatic tissue iron loading between Bmp6-deficient males and females, due to the suppressive effect of testosterone on hepcidin in males. In contrast to males, Bmp6-/- females still produce some hepcidin and do not massively accumulate iron in their pancreas, their heart or their kidneys. The goal of this study was to investigate the role of Hfe in the residual hepcidin production observed in the absence of Bmp6 in females. Mutations in the HFE gene are causing the most common form of hereditary hemochromatosis, a disorder characterized by a chronic inappropriate increase in dietary iron uptake, progressive iron overload and tissue injury. Human patients and mouse models of HFE-related hemochromatosis show inappropriately low expression of hepcidin. However, the mechanism by which HFE influences hepcidin expression is still unclear. In Hfe-/- mice and in patients with HFE-associated hemochromatosis, the induction of BMP6 mRNA by iron is intact, but hepcidin production is impaired. In the mouse, Hfe and Bmp6 genes are separated by less than 8 cM on chromosome 13, and the probability of obtaining recombinants between the 2 loci is low. However, HFE is a non-classical MHC class 1-like molecule which associates with β2-microglobulin and β2m-/- mice develop spontaneously hepatic iron overload with a distribution similar to that seen in the liver of Hfe-/- mice. We therefore generated β2m/Bmp6 double knockout mice in which the function of both Hfe and Bmp6 is impaired. Briefly, Bmp6-/- mice on a CD1 background were mated to β2m-/- mice on a C57BL/6 background and double heterozygote F1 mice were intercrossed. We assessed Smad1/5/8 phosphorylation, hepcidin expression, and the sites of iron accumulation in wild-type, simple knockout (β2m-/- or Bmp6-/-) and double knockout (β2m-/- and Bmp6-/-) mice of the F2 progeny. Interestingly, the lack of functional Hfe in Bmp6-/- females led to a much more severe phenotype than the single impairment of Bmp6, with massive iron loading in extrahepatic tissues, most notably the exocrine pancreas, the heart, and the proximal and distal convoluted tubules of the kidney. Phosphorylation of Smad1/5/8 in double knockout (β2m-/- and Bmp6-/-) mice was virtually abolished and hepcidin mRNA in double knockout females was much more strongly downregulated than in single Bmp6-/- females. In contrast to Bmp6-/- females, no protein was detectable by ELISA in double knockout mice. Our findings show that Bmp6 and Hfe regulate hepcidin production by two independent pathways that converge on Smad1/5/8 phosphorylation. The role of transferrin receptor 2 (TFR2), another hemochromatosis-associated molecule, remains a key question. The total suppression of hepcidin in mice in which both Hfe and Bmp6 have been impaired suggests that TFR2 does not regulate hepcidin through an additional pathway. Moreover, the observation that Hfe-/-/Tfr2-/- mice have a more severe phenotype than simple Hfe-/- or Tfr2-/- mice favors the interference of Tfr2 with the Bmp6 pathway. Comparison of the phenotype of mice with inactivation of both Bmp6 and Tfr2 to that of Bmp6-/- mice is likely to definitively solve this still open question. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3848-3848
    Abstract: Introduction: The Spectra Optia Apheresis System has been in use in our centre for 3 years for the collection of autologous peripheral blood stem cells (PBSC).We compared the Collection Efficiency (CE2) of the two Optias we have in use and also compared the CE2 of patients with Multiple Myeloma (MM) and Lymphomas, and those mobilised with and without Plerixafor. The Collection Efficiency (CE2) is calculated as follows: (Total CD34+ collected)/ (Whole Blood volume processed x Pre-CD34+ count). It is a crude estimation of the potential yield of a harvest and assumes that the CD34+ concentration is constant throughout a procedure. As the concentration of CD34+ cells in the peripheral blood will naturally drop off during a procedure, the CE2 can be expected to give a result that underestimates the yield. The pre-harvest FBC would normally be taken about 3 hours prior to commencement of the harvest, thus the peripheral CD34 may not fully reflect the count immediately before starting the harvest and this may also influence the accuracy of the CE2 result. Patients and Methods: Data on 143 peripheral blood autologous stem cell harvests from 87 patients collected using the Spectra Optia from mid-2011 to mid-2014 have been examined. Procedures without pre-harvest CD34+ counts or incomplete were excluded from the analysis. Procedures included in the analysis (138) are summarised in table 1. Median age of patients was 59 years (range 26-69). All patients were mobilised using disease specific standard protocols. Patients who fail to mobilise by the expected date were frequently given Plerixafor. A CD34+ dose of 5 x 106/kg was used as desirable target for reinfusion with enough for two reinfusion collected for MM patients to allow for repeat reinfusion if required. Statistical Analysis: Statistical analysis was performed using SPSS package. We have compared the CE2 achieved by each Optia machine, the CE2 results of the 2 main diseases MM and Lymphomas and to determine if any difference in Collection Efficiency is evident when patients are mobilised using Plerixafor. Results: 143 collections were included in the analysis. Fifty patients underwent one collection, 27 patients underwent two collections, and 10 patients required three collections to achieve the minimum CD34+ cell dose required. The mean CE2 for the entire cohort was 74.23% and mean CD34+ yield was 4.6 x 106/kg/collection. There were no statistically significant differences in pre-collection CD34+ count, collection efficiencies and final CD34+ yield between groups according to instruments used, administration of Plerixafor and diseases (Table 1). A significant correlation between the Preleukapheresis peripheral blood CD34+ cell count and the CD34+ cell yield of each leukapheresis was shown by a linear regression analysis (r2 = 0.867, p 〈 0.0001; Figure 1). Conclusions: For maximisation of PBSC yield, the timing for PBSC collection after these mobilizations is critical. Among criteria utilized to predict yield, the circulating peripheral blood CD34+ cell count has been a good predictor of PBSC yield mobilized with protocols used in our centre. In our data, pre-leukapheresis peripheral blood CD34+ cell count on the day of collection correlates with the final CD34+ yield. Interestingly, administration of Plerixafor in patients clinically at risk of poor mobilisation allows collection of comparable quality to patients who mobilised without Plerixafor. Abstract 3848. Table 1. Characterisation of collections, including device used, disease indication and use of Plerixafor. CD34_CE2 Periph_cd34 Actual yield Mean SD Number of procedures Mean SD Number of procedures Mean SD Number of procedures Optia 1 80.89% 85.37% 62 51.8 43.9 62 4.733 4.379 62 2 68.69% 17.38% 73 49.7 48.4 73 4.630 3.834 73 disease lymphoma 73.66% 28.94% 57 51.1 57.2 57 4.581 4.608 57 myeloma 75.39% 76.69% 73 52.7 36.5 73 5.008 3.651 73 other 65.45% 11.13% 5 15.4 12.0 5 .945 .677 5 Plerixafor no 73.79% 64.18% 107 55.1 47.6 107 5.078 4.208 107 yes 76.19% 35.77% 28 33.7 36.6 28 3.144 3.155 28 Total 74% 135 50.60 46.20 135 4.680 4.080 135 Fig. 1. Relation between pre-leukapheresis CD34+ count and actual leukapheresis yield. Fig. 1. Relation between pre-leukapheresis CD34+ count and actual leukapheresis yield. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Journal of Lipid Research, Elsevier BV, Vol. 48, No. 3 ( 2007-03), p. 543-552
    Type of Medium: Online Resource
    ISSN: 0022-2275
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2007
    detail.hit.zdb_id: 80154-9
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Critical Care Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 39, No. 10 ( 2011-10), p. 2300-2307
    Type of Medium: Online Resource
    ISSN: 0090-3493
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2011
    detail.hit.zdb_id: 197890-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Transfusion and Apheresis Science, Elsevier BV, Vol. 56, No. 4 ( 2017-08), p. 563-565
    Type of Medium: Online Resource
    ISSN: 1473-0502
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 2046795-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Marine Drugs, MDPI AG, Vol. 16, No. 5 ( 2018-04-27), p. 146-
    Abstract: Herein, we describe the isolation and spectroscopic identification of eight new tetrabrominated tyrosine alkaloids 2–9 from the Polynesian sponge Suberea ianthelliformis, along with known major compound psammaplysene D (1), N,N-dimethyldibromotyramine, 5-hydroxy xanthenuric acid, and xanthenuric acid. Cytotoxicity and acetylcholinesterase inhibition activities were evaluated for some of the isolated metabolites. They exhibited moderate antiproliferative activity against KB cancer cell lines, but psammaplysene D (1) displayed substantial cytotoxicity as well as acetylcholinesterase inhibition with IC50 values of 0.7 μM and 1.3 μM, respectively.
    Type of Medium: Online Resource
    ISSN: 1660-3397
    Language: English
    Publisher: MDPI AG
    Publication Date: 2018
    detail.hit.zdb_id: 2175190-0
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Journal of Clinical Apheresis, Wiley, Vol. 34, No. 4 ( 2019-08), p. 359-366
    Abstract: Extracorporeal photopheresis (ECP) is an efficient and established therapy to treat acute and chronic graft vs host disease (GVHD). Using an “off‐line ” method, the first step (mononuclear cell [MNC] collection) is decisive, as long as a high MNC yield and purity in the collected product is desirable. Two “off‐line ” devices were compared: the COBE Spectra and the Spectra Optia (Terumo BCT), using both continuous and intermittent protocols. Patients and methods Twelve patients with GvHD (7 acute/5 chronic) were enrolled between June 2014 and May 2015 and were alternatively assigned for each procedure to either the COBE Spectra or the Spectra Optia cell separator. Patients characteristics and procedure/product parameters were analyzed. Results Two hundred procedures (100 per device) were included. The Spectra Optia system showed higher total nucleated cells and MNC collection efficiencies (18.6(10.2‐29.7) vs 7.9(4.1‐14.8)% and 43.6(20.3‐59.5) vs 23.3(11.4‐37.1)%, P   〈  .001) and monocyte and lymphocyte collection efficiencies (55.2(17.7‐83.2) vs 22.8(9‐38.9)% and 38.3(26.7‐53.4) vs 22.2(9‐38.9)%, respectively, P   〈  .001). Absolute platelet loss (PL) and PL per liter of blood processed were significantly lower in the Spectra Optia group (22.9(18.3‐28.1) vs 33.6(26.5‐41.1)%, P   〈  .001 and 3.7(3.1‐4.5) vs 4.3(3.5‐4.2)%, P  = .01, respectively). However, granulocyte contamination was higher (4.5(1.3‐36) vs 1.2(0.4‐5.7)%, P   〈  .001) and a higher product haematocrit was obtained with the Spectra Optia (1(0.5‐1.6) vs 0.3(0.2‐0.5)%, P   〈  .001), without an impact on irradiation time. Conclusions In our study, Spectra Optia proved to be safe and effective in collecting MNC with high yield and purity for ECP in GvHD.
    Type of Medium: Online Resource
    ISSN: 0733-2459 , 1098-1101
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2001633-5
    detail.hit.zdb_id: 604912-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...